Camargo

MAY 10, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Triple-negative breast cancer. First-line bladder cancer. First-line bladder cancer. Third-line stomach cancer.

Development 185

Development Clinical Trials Clinical Trials Trials 185

Drug Discovery World

JUNE 9, 2023

News round-up for 5-9 June by DDW Digital Content Editor Diana Spencer. Promising results for disitamab vedotin in bladder cancer RemeGen announced the latest clinical research results on disitamab vedotin (RC48) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Clinical Trials 52

Clinical Trials Clinical Trials Drugs Trials 52

pharmaphorum

JUNE 20, 2022

On the WSJ Merck/Seagen story, while it's great to hear news about any potential M&A or BD, there is some bad news in there. Merck is pairing the drug with its PD-1 inhibitor Keytruda (pembrolizumab), which dominates the checkpoint inhibitor category with approvals across 15 cancer types and annual sales of $17 billion.

Sales 103

Sales Marketing Drugs Licensing 103

The Pharma Data

JANUARY 2, 2021

Consumer News. 2, 2021 — A New Year’s resolution to take better care of yourself is one you should keep, especially in the era of COVID-19. For cancer prevention, the American Institute for Cancer Research and the American Cancer Society recommend maintaining a healthy weight, staying active and eating a healthy diet.

Research 52

Research 52

Delveinsight

AUGUST 24, 2021

Unpleasant news strike hard for their first deal in the rare neurodegenerative disease domain. ” USFDA Grants Clinical Trial Approval to Beijing HebaBiz Biotech’s Siroquine (JP001) – An Innovative Anti-Cancer Drug. Siroquine is an innovative anti-cancer drug under development based on the Autophagy mechanism.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Drugs 96

Drug Discovery World

NOVEMBER 1, 2023

Many drug discovery companies took the opportunity to share their latest cancer research findings. Amivantamab, Janssen Data from the Phase III MARIPOSA study showed amivantamab plus lazertinib improved PFS by 30% compared to osimertinib in patients with first-line advanced EGFR-mutated non-small cell lung cancer (NSCLC).

Clinical Trials 59

Clinical Trials Clinical Trials Trials HR 59

pharmaphorum

AUGUST 6, 2021

Sanofi and Regeneron’s latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with Merck & Co’s class leader Keytruda in the big non-small cell lung cancer (NSCLC) category. Merck claims adjuvant win in melanoma.

Trials 54

Trials Drugs Marketing Development 54

Drug Discovery World

APRIL 14, 2023

The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.

Genetics 52

Genetics Research Medicine Clinical Research 52

pharmaphorum

AUGUST 7, 2020

Roche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been dashed by a late-stage trial failure looking at the drug in combination with chemotherapy. It is more aggressive than other types of breast cancer, accounting for 15-20% of cases but causing 25% of deaths.

Trials 52

Trials Drugs Licensing Licensing 52

Delveinsight

SEPTEMBER 9, 2021

A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indications. A portion of the new funding will also be utilized to improve the Breath Biopsy platform.

FDA Approval 73

FDA Approval Development Research Production 73

Pharmaceutical Technology

JULY 22, 2022

Helen Branswell, an infectious diseases and health reporter at the news website Stat News, shared an article on a monkeypox case being reported in the US, amid rising cases in Spain, Portugal, and Europe. Long-term infections can cause damage to the liver and kidneys, and can cause infertility and bladder cancer.

Vaccination 130

Vaccination Vaccine Life Science Immune Response 130

The Pharma Data

JANUARY 24, 2021

Tackling cancer is a crucial topic and a priority for this region, and I am pleased that MU is able to contribute to the growth of innovative cancer research by taking part in this study” With the addition of MU, the Company now has 5 clinical study sites open in Canada and 3 in the US for patient enrollment and treatment for Study II.

Bacteria 52

Bacteria Containment Clinical Research Research 52

The Pharma Data

SEPTEMBER 6, 2021

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer. Breast Cancer Highlights. Lung Cancer Highlights. Roche’s Chief Medical Officer and Head of Global Product Development.

Genome 52

Genome Genomics HR Hormones 52

Pharma Times

MAY 1, 2024

Bladder cancer, including papillary tumours, is the ninth most common cancer type worldwide

Research 118

Research 118

pharmaphorum

DECEMBER 19, 2022

The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firedenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumours.

Gene Therapy 111

Gene Therapy FDA Approval Gene Drugs 111

Drug Discovery World

FEBRUARY 7, 2024

Astellas has submitted a supplemental new drug application (sNDA) in Japan for Padcev (enfortumab vedotin (genetical recombination)) with Keytruda (pembrolizumab (genetical recombination)) for the first-line treatment of advanced bladder cancer.

Regulation 52

Regulation Containment Genetics Clinical Trials 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. Orgovyx: The First Oral GnRH Antagonist for Advanced Prostate Cancer. Prostate cancer is the second leading cause of death due to cancer in men in the U.S. Margenza Cleared to Treat Metastatic HER2-Positive Breast Cancer. . Professional.

FDA Approval 52

FDA Approval Vaccination Vaccine Hormones 52

Drug Discovery World

DECEMBER 20, 2023

The US Food and Drug Administration (FDA) has approved antibody-drug conjugate (ADC) enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer (la/mUC). It is directed to Nectin-4, a protein highly expressed in bladder cancer.

FDA Approval 52

FDA Approval Antibody Trials Drugs 52

Drug Discovery World

SEPTEMBER 14, 2023

Europe has one of the highest rates of bladder cancer in the world 1 , with more than 203,000 patients diagnosed in 2020 alone 2. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Erdafitinib for the treatment of metastatic bladder cancer.

Containment 52

Containment Genetics FDA Approval Marketing 52

The Pharma Data

NOVEMBER 30, 2020

30, 2020 — The incidence of and mortality rates for breast and colorectal cancers do not differ for individuals with and without multiple sclerosis (MS), while bladder cancer incidence and mortality rates are higher for MS patients, according to a study published online Nov. MONDAY, Nov. 25 in Neurology.

Development 52

Development Research 52

pharmaphorum

MARCH 9, 2021

As with AstraZeneca’s Imfinzi in previously treated bladder cancer, Merck & Co’s Keytruda in previously treated metastatic small cell lung cancer , and Bristol-Myers Squibb’s Opdivo in small cell lung cancer after chemo , the FDA has asked for indications to be axed after the required overall survival data failed to emerge.

Marketing 97

Marketing Medicine Drugs Trials 97

XTalks

DECEMBER 27, 2022

Ferring Pharmaceuticals announced that the US Food and Drug Administration (FDA) approved Adstiladrin (nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 8, 2023

Following this, in December, the FDA approved Adstiladrin (nadofaragene firadenovec-vncg) as the first gene therapy for the treatment of high-risk, non-muscle invasive bladder cancer. Therefore, the good news is we have flexibilities that can be offered to see drug development for these diseases.”

Gene Therapy 264

Gene Therapy Gene Trials Clinical Trials 264

Scienmag

MAY 14, 2022

New York, NY (May 14, 2022) — Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results presented at the American Urological Association (AUA) annual (..)

Clinical Trials 73

Clinical Trials Clinical Trials Trials 73

pharmaphorum

NOVEMBER 29, 2022

Genentech, a member of the Roche Group , has announced that it is voluntarily withdrawing the US indication of Tecentriq (atezolizumab) for the treatment of adult patients with certain types of metastatic bladder or urinary tract cancer. Of those, circa 30% are considered advanced based on muscle-invasive or metastatic disease.

Containment 52

Containment Antibody Trials Development 52

Scienmag

FEBRUARY 15, 2022

Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.

Clinical Trials 76

Clinical Trials Clinical Trials Trials 76

Scienmag

JULY 3, 2022

Researchers who treated a group of post-surgery bladder cancer patients with the immunotherapy drug atezolizumab have found that patients whose blood contained circulating tumour DNA (ctDNA), responded very well to the treatment. The study is presented today at the European Association of Urology annual congress (EAU22), in Amsterdam.

DNA 67

DNA Containment Research Drugs 67

pharmaphorum

AUGUST 22, 2021

Bristol-Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer therapy, getting FDA approval for the drug for post-surgical treatment of invasive bladder cancer. BMS also has positive clinical results for Opdivo as an adjuvant treatment for non-small cell lung cancer (NSCLC).

FDA Approval 76

FDA Approval Drugs Medicine Trials 76

Scienmag

JULY 7, 2022

The median age for receiving a bladder cancer diagnosis is 73, and a significant number of those living with the disease are in their 70s and 80s. A longstanding stereotype in cancer care is that older patients favor a more paternalistic style of care, one in which they defer to the authority of a care provider and […].

63

63

Scienmag

APRIL 11, 2022

**Strictly under embargo until 23:30 (BST) Monday 11 April 2022** Phase two randomised placebo controlled trial (NEOBLADE) showed giving patients nintedanib, as well as chemotherapy before surgery or radiotherapy, significantly increased overall survival rates at one, two and five years Nintedanib belongs to a group of targeted therapy drugs known (..)

Drugs 64

Drugs Trials 64

pharmaphorum

APRIL 7, 2022

Last year, NICE said that Merck KGaA/Pfizer’s Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only cancer immunotherapy approved for this use.

Pharma Companies 52

Pharma Companies Clinical Trials Clinical Trials Drugs 52

pharmaphorum

MARCH 18, 2021

NICE has axed funding for MSD’s Keytruda for second-line advanced bladder cancer in final guidance, despite an appeal from the company. But the data from this trial showed an improvement in overall survival but not in progression-free survival, a measure of how long a treatment can keep patients alive without the cancer spreading.

Manufacturing 52

Manufacturing Medicine Trials Development 52

pharmaphorum

SEPTEMBER 30, 2021

NICE has recommended routine NHS access to Roche’s cancer immunotherapy Tecentriq for some bladder cancer patients, four years after it was first made available via the Cancer Drugs Fund (CDF). ” The post NICE clears NHS use of Roche’s Tecentriq in bladder cancer appeared first on. .

Medicine 52

Medicine Drugs Production Marketing 52

pharmaphorum

AUGUST 9, 2021

Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance treatment with Merck Serono and Pfizer’s Bavencio, ahead of their counterparts in England and Wales. Bavencio was one of six new medicines recommended by the SMC for routine coverage by NHS Scotland.

Medicine 52

Medicine Drugs Marketing 52

pharmaphorum

AUGUST 18, 2020

The FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that will halve the number of required clinic visits for patients with lung and bladder cancer. The post AZ aims to cut cancer clinic visits with new Imfinzi regimen appeared first on.

Doctors 52

Doctors Doctor Compliance Trials 52

pharmaphorum

MAY 7, 2021

Merck Serono’s Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE says it is too expensive to justify routine NHS use. .

Containment 52

Containment Drugs Trials 52

pharmaphorum

APRIL 20, 2021

The next milestone in Seagen and Astellas’ bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster will come in August, when the FDA concludes an accelerated review of two bladder cancer filings. . The post Astellas, Seagen seek speedy reviews of Padcev in bladder cancer appeared first on.

Antibody 52

Antibody Sales Drugs Trials 52